Key Points {#FPar1}
==========

We report a life-threatening reaction, possibly from topical 0.5% 5-fluorouracil cream, which is a lower strength dose than the only reported case of a life-threatening adverse event with 5.0% 5-fluorouracil cream.Given the common use of topical 5-fluorouracil cream, it is important for clinicians to consider the adverse side effects that can occur, especially in patients with a dihydropyrimidine dehydrogenase deficiency.

Introduction {#Sec1}
============

5-Fluorouracil (5-FU) is a common chemotherapeutic for the treatment of different malignancies, including carcinomas of the gastrointestinal tract, breast, and skin \[[@CR1]\]. The rate-limiting enzyme in the catabolic pathway is dihydropyrimidine dehydrogenase (DPD), and studies have shown that decreased DPD activity leads to less drug clearance and increased toxicity \[[@CR1]\]. Toxicities from systemic exposure include diarrhea, stomatitis, mucositis, pancytopenia, sepsis, cardiotoxicity, and---in some cases---death \[[@CR2], [@CR3]\]. The treatment for actinic keratosis includes cryotherapy, topical 5-FU, topical imiquimod, topical diclofenac, photodynamic therapy, and surgical excision. Topical 5-FU has been a gold standard treatment for years, especially with multiple lesions \[[@CR4]\]. The most common side effects from topical 5-FU include skin irritation with associated erythema, dryness, and burning \[[@CR4]\]. Very few reports of severe adverse reactions from topical 5-FU exist, but reactions include allergic contact dermatitis and inflammatory colitis \[[@CR4]\]. Only one known life-threatening case of toxicity has been reported from topical 5-FU \[[@CR1]\], but this case was reported after 5% 5-FU. To our knowledge, no similar adverse event has been reported with the lower-strength 0.5% 5-FU in the literature.

Case Report {#Sec2}
===========

We report the case of an otherwise healthy 67-year-old man with no past medical history who presented with multiple actinic keratoses of the face, neck, and forearms. He was prescribed 0.5% 5-FU topical cream, which was to be applied to the skin daily for 30 days on his bilateral forearms. He was receiving no other medications that could have caused adverse interactions. After 1 week of topical use, he reported extreme lethargy, fatigue, fever, and mouth erosions. The medication was discontinued immediately. Physical examination revealed erythematous, scaly, and erosive plaques located on the bilateral anterior forearms (Fig. [1](#Fig1){ref-type="fig"}a) and multiple small ulcers of the hard palate. Several days after discontinuation of 5-FU, painful mucositis (Fig. [1](#Fig1){ref-type="fig"}b) and systemic 5-FU side effects occurred, including severe mucositis with mouth ulcerations, anorexia, 15-pound weight loss, and dehydration. No diarrhea was noted. The patient's white blood cell count was normal. These systemic effects met criteria for hospitalization. Viral, bacterial, and fungal cultures of the mouth were negative, confirming a medication-induced mucositis. Complete blood count (CBC) and comprehensive metabolic panel (CMP) revealed dehydration but no signs of active infection or immunosuppression. Hematology/oncology was consulted, which stated that this presentation was likely due to a systemic 5-FU reaction, similar to the intravenous chemotherapy reaction seen with 5-FU. However, the patient refused DPD deficiency testing, so confirmation of deficiency could not be obtained. Supportive treatment along with intravenous fluids were administered for management. The medication was stopped before more possible adverse reactions, such as severe diarrhea or bone marrow suppression, were observed. The mucositis and systemic symptoms took approximately 1 month to resolve.Fig. 1**a** Forearms post 1-week of nightly 0.5% 5-FU topical cream; **b** oral mucositis post 1-week with nightly 0.5% 5-FU cream

Discussion and Conclusion {#Sec3}
=========================

Johnson and Diasio \[[@CR5]\] reported the first patient with cancer known to develop life-threatening reactions after treatment with topical 5% 5-FU. This patient was found to be deficient in DPD, which contributed to the life-threatening toxicity. Review of the literature suggests approximately 3--5% of the general population have partial DPD deficiency \[[@CR3]\]. In addition, DPD deficiency has been reported to be responsible for at least 50% of severe 5-FU treatment toxicity \[[@CR3]\]. Further, 5-FU has been shown to have a narrow therapeutic index, and the literature also demonstrates it has a marked individual pharmacokinetic variability \[[@CR6]\]. Therefore, a certain dose may produce a therapeutic response in one individual but a possible life-threatening toxicity in another \[[@CR7], [@CR8]\].

Because 5-FU is commonly used, and severe toxicity effects are associated with DPD deficiency, several methods have been developed to detect DPD deficiency. These include genotyping, radio-immunoassays, and measuring serum uracil concentrations, but these tests are expensive and time-consuming \[[@CR9]\]. Given the rarity of life-threatening adverse events caused by topical 5-FU, developing a test to detect DPD deficiency would be more suitable for systemic therapy.
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